Sosale Nisha G, Ivanovska Irena I, Tsai Richard K, Swift Joe, Hsu Jake W, Alvey Cory M, Zoltick Philip W, Discher Dennis E
Biophysical Engineering Labs, University of Pennsylvania , Philadelphia, Pennsylvania, USA.
Pharmacological Sciences Graduate Group, University of Pennsylvania , Pennsylvania, USA.
Mol Ther Methods Clin Dev. 2016 Dec 7;3:16080. doi: 10.1038/mtm.2016.80. eCollection 2016.
Lentiviruses infect many cell types and are now widely used for gene delivery , but uptake of these foreign vectors by macrophages is a limitation. Lentivectors are produced here from packaging cells that overexpress "Marker of Self" CD47, which inhibits macrophage uptake of cells when prophagocytic factors are also displayed. Single particle analyses show "hCD47-Lenti" display properly oriented human-CD47 for interactions with the macrophage's inhibitory receptor SIRPA. Macrophages derived from human and NOD/SCID/Il2rg (NSG) mice show a SIRPA-dependent decrease in transduction, , transgene expression, by hCD47-Lenti compared to control Lenti. Consistent with known "Self" signaling pathways, macrophage transduction by control Lenti is decreased by drug inhibition of Myosin-II to the same levels as hCD47-Lenti. In contrast, human lung carcinoma cells express SIRPA and use it to enhance transduction by hCD47-Lenti- as illustrated by more efficient gene deletion using CRISPR/Cas9. Intravenous injection of hCD47-Lenti into NSG mice shows hCD47 prolongs circulation, unless a blocking anti-SIRPA is preinjected. transduction of spleen and liver macrophages also decreases for hCD47-Lenti while transduction of lung carcinoma xenografts increases. hCD47 could be useful when macrophage uptake is limiting on other viral vectors that are emerging in cancer treatments (, Measles glycoprotein-pseudotyped lentivectors) and also in targeting various SIRPA-expressing tumors such as glioblastomas.
慢病毒可感染多种细胞类型,目前广泛用于基因递送,但巨噬细胞对这些外源载体的摄取是一个限制因素。慢病毒载体在此由过表达“自我标记”CD47的包装细胞产生,当也展示促吞噬因子时,CD47会抑制巨噬细胞对细胞的摄取。单颗粒分析表明,“hCD47-慢病毒”展示了正确定向的人CD47,用于与巨噬细胞的抑制性受体SIRPA相互作用。与对照慢病毒相比,源自人和NOD/SCID/Il2rg(NSG)小鼠的巨噬细胞显示,hCD47-慢病毒介导的转导、转基因表达因SIRPA依赖性而降低。与已知的“自我”信号通路一致,通过药物抑制肌球蛋白-II,对照慢病毒介导的巨噬细胞转导降低到与hCD47-慢病毒相同的水平。相比之下,人肺癌细胞表达SIRPA,并利用它来增强hCD47-慢病毒介导的转导,如使用CRISPR/Cas9进行更有效的基因缺失所示。将hCD47-慢病毒静脉注射到NSG小鼠体内显示,hCD47可延长其循环时间,除非预先注射阻断性抗SIRPA抗体。hCD47-慢病毒介导的脾脏和肝脏巨噬细胞转导也会减少,而肺癌异种移植瘤的转导则会增加。当巨噬细胞摄取限制癌症治疗中出现的其他病毒载体(如麻疹糖蛋白假型慢病毒载体)时,以及在靶向各种表达SIRPA的肿瘤(如胶质母细胞瘤)时,hCD47可能会有用。